News | February 26, 2015

Three-dimensional device helps track tumor site after lumpectomy for more precise radiation treatment

BioZorb, Focal Therapeutics, breast cancer, Schonholz, conference

February 26, 2015 — A Noble Hospital breast surgeon's work with a new device that improves treatment of breast cancers will be featured later this month at a prestigious international medical conference.

Steven Schonholz, M.D., FACS, will present a scientific poster at the 32nd annual Miami Breast Cancer Conference, in Miami Beach, Fla., Feb. 26 to March 1. Schonholz will focus on BioZorb, a novel three-dimensional bioabsorbable surgical marker which helps physicians track the tumor site after lumpectomy surgery to remove cancer and deliver more precise radiation treatment.

Schonholz was the first physician in Massachusetts to use BioZorb as part of his medical practice. He is director of the Center for Comprehensive Breast Health at Noble Hospital.

BioZorb contains several tiny titanium clips positioned in a 3-D pattern inside a bioabsorbable coil. The body eventually resorbs the coil, leaving the titanium clips for long-term visualization of the surgery site.

"This unique device does a better job of helping us protect healthy tissue around the surgical site during radiation therapy," said Schonholz. "It can also provide our patients with a more satisfying cosmetic result after treatment."

The work by Schonholz that is being recognized at the Miami conference includes an infographic explaining how BioZorb is used in the treatment of breast cancer. Among advantages of the marker that are outlined in the infographic are these:

  • It is readily placed by the surgeon and can be easily visualized.
  • It helps target the radiation therapy to a smaller target area which results in less radiation to normal tissues.
  • It provides a stable 3-D identification of where the tumor was prior to removal, to help with treatment and longer-term follow-up.

 

Preliminary experience suggests the BioZorb infographic effectively informs patients and clinicians about an advanced tissue marking method and improves communication between the breast surgeon and radiation oncologist, according to the poster.

For more information: www.noblehospital.org


Related Content

News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
Subscribe Now